Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations.
Patterns of mutations associated with didanosine (ddI) resistance are still a controversial issue. The correlation between different clusters of reverse transcriptase mutations with the short-term virological activity of ddI when added to a failing regimen was examined in 40 patients. The median fall in plasma viral load at week 4 was 0.67 log10 copies/ml. There was good correlation between the median fall in plasma HIV RNA levels and the number of nucleoside-associated (P = 0.0152) or thymidine-associated (P = 0.0142) mutations. In conclusion, ddI retained substantial antiretroviral activity when the number of nucleoside-associated or thymidine-associated mutations was less than four.
Blanco
Jose Luis
JL
Infectious Diseases Unit, University of Barcelona, Spain. jlblanco@clinic.ub.es
Biglia
Alejandra
A
De Lazzari
Elisa
E
Mallolas
Josep
J
Martinez
Esteban
E
Pumarola
Tomás
T
Larrousse
María
M
Milinkovic
Ana
A
León
Agathe
A
Lonca
Montserrat
M
Laguno
Montserrat
M
Gatell
Josep María
JM
D016049:Didanosine / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000235:genetics; D006801:Humans; D009154:Mutation; D009705:Nucleosides / Q000235:genetics; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013936:Thymidine / Q000235:genetics; D016896:Treatment Outcome; D019562:Viral Load
D009705:Nucleosides; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase; D016049:Didanosine; D013936:Thymidine